← SynDRA
PIMOZIDE
SynDRA canonical compound SYN0006402 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | HTR2A |
|---|
| Mechanism of action | Dopamine receptor antagonist |
|---|
| Indication | Tourette's disorder |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- DRD2
- DRD3
- HTR2A
- DRD4
- CACNA1I
- DRD1
- HTR1A
- DRD5
- KCNA10
- HRH1
- CACNA1H
- KCNH2
Mechanisms of action (all sources)
- Dopamine receptor antagonist
- HTR2A ANTAGONIST
- Serotonin 2a (5-HT2a) receptor antagonist
- DRD2 ANTAGONIST
- DRD3 ANTAGONIST
- DRD5 ANTAGONIST
- DRD4 ANTAGONIST
- DRD1 ANTAGONIST
- HTR1A ANTAGONIST
- CACNA1H PORE BLOCKER
- CACNA1I ANTAGONIST
- HRH1 ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- CACNA1C
- SLC6A4
- SLC6A3
- SLC6A2
- SCN5A
- PPARG
- MTOR
- MC3R
- HRH2
- ESR2
- ESR1
- CYP3A4
- CHRM2
- CHRM1
- CCKAR
- HTR2B
- ADRB3
- ADRB1
- ADORA3
- ADRB2
- AVPR1A
- NR3C1
- POLK
- POLI
- PMP22
- PGR
- PDE4D
- PDE4A
- PDE3A
- NTSR1
- NR1I2
- NR1H4
- NPY2R
- NPY1R
- NPSR1
- NFKB1
- NFE2L2
- MPHOSPH8
- MLNR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT1A
- RXFP1
- MDM4
- MDR1
- MK01
- MMP14
- NSD2
- NTR1
- PIP4K2A
- PRGR
- RARA
- SCN10A
- ACM1
- SCN11A
- SCN1A
- SCN3A
- SCN4A
- SCN7A
- SCN8A
- SCN9A
- STK33
- TPO
- MDM2
- M4K2
- KCA10
- IL1B
- ANDR
- APAF
- CAC1H
- CAC1I
- CACNA1D
- CACNA1F
- CACNA1S
- CASP3
- CASP7
- CP19A
- CP1A2
- CP2C9
- CP2CJ
- CP2D6
Drug classes
- Anti-Dyskinesia Agents
- Antipsychotic Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Dopamine Agents
- Dopamine Antagonists
- Neurotransmitter Agents
- Psychotropic Drugs
- Tranquilizing Agents
- Typical Antipsychotic
ATC classes
Cross-references
Synonyms
- ORAP
- primozide
- R6238
- R-6238
- Pimozida
- MCN-JR-6238
- NSC-170984
- R-623
- Orap
- Antalon
- Neoperidole
- Opiran
- Pimozidum
- Primozida
- ASTA Medica Brand of Pimozide
- Janssen Brand of Pimozide;Orap forte
- Pharmascience Brand of Pimozide
- P 1793
- McN-JR-6238
- Orap (TN)
- Pimozida [INN-Spanish]
- Pimozidum [INN-Latin]
- Primozida [INN-Spanish]
- Pimozide (JAN/USP/INN)
- Pimozide [USAN:INN:BAN:JAN]
- McN-JR 6238
- pimozide (usp-rs)
- R 6238
- pimozide (ep monograph)
- pimozide (usp monograph)
- 1HIZ4DL86F
- NSC 170984
- pimozida
- NSC170984
- CHEBI:8212
- DTXCID803474
- Orap forte
Reported adverse events
- Akathisia
- Akinesia
- Asthenia
- Constipation
- Depression
- Dizziness
- Dyskinesia
- Dysphagia
- Eructation
- Headache
- Hyperkinesia
- Hyperpyrexia
Look up PIMOZIDE in the interactive SynDRA portal →